Its adjuvant properties result from induction of type I interferons and pro-inflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF), and interleukin (IL)−1β8 thus enabling an improved efficacy of cancer immunotherapy in murine tumor models9–11. This evidence concerns the gene TNF and cancer.